Jaka jest cena za MetaVia Inc. (MTVA)

Cena za MetaVia Inc. (MTVA) wynosi $1.51

Jaka jest kapitalizacja rynkowa dla MetaVia Inc. (MTVA)

Kapitalizacja rynkowa dla MetaVia Inc. (MTVA) wynosi $3.32M

MetaVia Inc. (MTVA) Historia Cen

Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.

Rok	Wydajność
2026 (TTM)	-43.25%
2025	-62.61%
2024	0.00%

Rok

Wydajność

2026 (TTM)

-43.25%

2025

-62.61%

2024

0.00%

Firma	Cena akcji	Zmiana 1r%	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	$505.24	28.63%	US
Argenx SE ARGX.US	$846.09	29.41%	NL
Lonza Group AG LONN.SW	$731.69	6.47%	CH
Samsung Biologics Co.,Ltd. 207940.KS	$1.07K	-6.40%	KR
UCB S.A. UCB.BR	$251.82	11.75%	BE

Firma

Cena akcji

Zmiana 1r%

Kraj